Brain Tumor Treatments: ONC-201
Braintumor Website

Last updated: 3/22/18

ONC201 is an experimental, orally bioavailable, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity.

Clinical Trials

  1. ONC-201 for Recurrent Glioblastomas and H3 K27M-mutant Gliomas.
  2. ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
  3. ONC201 in Pediatric H3 K27M Gliomas

Scientific Publications

  1. Research Abstracts presented at 2018 AACR meeting

Videos

  1. Dr. Minesh Mehta Speaks About Neuro-Oncology and the Opportunities Presented by ONC201



  2. Phase II Trial in Glioblastoma with ONC201, a First in Class DRD2 Antagonist




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740